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Stoichiometry of the T cell Antigen Receptor (TCR)
Complex: Each TCR/CD3 Complex Contains One
TCR ol, One TCR [3, and Two CD3e Chains
By Jennifer A. Punt, Joseph L. Roberts, Kelly P. Kearse,
and Alfred Singer
From the Experimental Immunology Branch, National Cancer Institute, Bethesda, Maryland
20892

Snnlmgary

he TCR, a heterodimer of ot and/5 proteins, is expressed
on the surface o f t lymphocytes as part ofa multisubunit
T
complex that includes the CD3 proteins (CD33,, tS, and e)
and a dimer of the ~'protein family (1). Although all members
of the surface TCR/CD3 complex have been identified, their
stoichiometry has not yet been completely determined. Recent studies showing that at least two, and possibly only two,
CD3e proteins are present per TCR/CD3 complex have led
to a reevaluation of TCR/CD3 structure and the proposal
that CD3 components exist in a single complex as two dimers
of 3'/e and ~/~ proteins (2-4). Several groups have also raised
the possibility that there are two TCR a and two TCR
chains in a single TCR complex (5, 6), arguing that such
an arrangement would facilitate signal transduction after TCR
engagement by antigen and would result in an electrostatically neutral and, hence, more stable protein complex.
To determine whether there were more than one TCR ot
or TCR/3 protein in a single TCR/CD3 complex, we examined associations among components of surface TCR on
thymocytes and splenic T cells coexpressing two different TCR
ot and two different TCR ~ chains. The results of these experiments provide a unique solution to the stoichiometry of
the TCR/CD3 complex and demonstrate that there are only
one TCR ot chain, one TCR ~ chain, and two CD3 e chains
in a single TCR/CD3 complex.
587

Materials and Methods
Mice. Mice transgenic for the A N D TCR ot and/~ chains (7)
were originally provided by S. Hedrick (University of California
at San Diego, La Jolla, CA) and were bred in our facility. They
had been backcrossedfor more than 10 generationsonto a C57BL/6LyS.2 background. Mice transgenic for the anti-H-Y TCR a and
/~ chains (8) were originally provided by H. von Boehmer (Basel
Institute, Basel, Switzerland) and were bred in our facility.Double
transgenic mice were generated by crossing a mouse heterozygous
for the AND transgenes with a mouse heterozygous for the antiH-Y transgenes. Progeny were screenedfor the expressionof transgenic TCR products by examining PBL for surface expression of
the AND TCR ct (ANDVc~11)and the anti-H-Y TCR/3 ("-vVa8)
chains. Femalesingle and double TCR transgenic animalswere used
in these studies.
Antibodies. BiotinylatedmAbs anti-V~11 (RR8-1 [9]) and antiVa3 (KJ-25 [10]) are specific for the AND TCR cr and TCR/~
chains, respectively,were purchased from PharMingen (San Diego,
CA). T3.70, the mAb specificfor the anti-H-Y TCR ot chain V~3,
was provided by H. von Boehmer (8) and conjugated to FITC in
our lab. mAb anti-Va8.1, 8.2, 8.3 (F23.1 [11]) binds the anti-H-Y
TCR ~ chain and was purified and conjugated to FITC in our lab.
mAb anti-CD3e (145-2Cll [12]) was used as a hybridoma supernatant for precipitations and as a protein A-purified preparation
for quantitativesurfacestaining. Both mAb anti-CD3e (500A2 [13])
and mAb anti-TCR B (H57-597 [14]) were also used as protein
A-purified preparations for quantitative surface staining.

The Journal of Experimental Medicine 9Volume 180 August 1994 587-593

Downloaded from jem.rupress.org on March 29, 2013

The stoichiometry of the subunits that comprise the T cell antigen receptor (TCR) complex
is not completely known. In particular, it is uncertain whether TCR ot and TCR/5 proteins
are present in the TCR complex as one or multiple heterodimeric pairs. In this study we have
used mice transgenic for two different TCR ot and two different TCR/5 proteins to determine
the number of TCR a and TCR/5 chains in a single TCR complex. Individual thymocytes
and splenic T cells from double TCR transgenic mice simultaneously expressed all four transgenic
TCR proteins on their surfaces. Because the individual TCR ot and individual TCR/5 proteins
were biochemically distinguishable, we were able to examine associations among the transgenic
TCR products. We found that each TCR ct chain paired with each T C R / 5 chain, but that
each TCR complex contained only one TCR ot and one TCR B protein. Furthermore, quantitative
immunofluorescence revealed that T cells expressed twice as many CD3e as TCR/5 proteins.
These findings demonstrate that there are precisely one TCR a, one TCR/5, and two CD3e
chains in each TCR/CD3 complex expressed on the surfaces of both thymocytes and mature T cells.
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Surface Ioaination, Immunoprecipitation, and Endoglycosidase-F
(Endoy F Digestion. Cells were pelleted, washed with cold PBS
and treated with Bolton Hunter reagent (18) before they were surface iodinated as described previously (19). Surface iodinated cells
were lysed in 1% digitonin as described previously (19) and immunoprecipitated with beads preadsorbed to fetal calf serum, then with
beads preadsorbed to 2-4 #g purified antibody (anti-V~11, antiVa3) or 1 ml hybridoma supematant (F23.1, T3.70, and 2Cll).
Immunoprecipitates were washed in buffer containing 0.2%
digitonin (18) and digested overnight with Endo F/Peptide-NGlycosidase F (Endo F/PNGase F) (Oxford Glycosystems, Rosedale, NY) at 37~ as per the manufacturer's instructions.
Two-dimensionalNEPHGE/SDS-PAGE Electrophoresis. Immunoprecipitated samples were equih'brated in 150 #1 sample buffer
(9.5 M urea, 2% Triton X-100, 1.6% Ampholyte 5-7 [Bio-Rad
Laboratories, Richmond, CA], 0.4% Ampholyte 3-10 [Bio-Rad
Laboratories], 5% 2-mercaptoethanol) and separated in tube gds
across a pH gradient (nonequilibrium pH gradient electrophoresis
[NEPHGE]) for 2500 volt-hours as described previously (18, 20).
Tube gels were extruded, equilibrated at 37~ in SDS-PAGEsample
buffer containing 2-mercaptoethanol and run in the second dimension on a 13% reducing PAGE gel. Gels were run for 865 Vh,
fixed, dried, and visualized by phosphorimagery.

Results

Experimental Design. The stoichiometry of the TCR/CD3
complex has not yet been solved and a number of TCR/CD3
configurations are consistent with current data (Fig. 1). Vat1 Abbreviations used in this pa~r: Endo F, Endoglycosidase F; NEPHGE,

nonequilibrium pH gradient dectrophoresis; PNGase F, Peptide-NGlycosidaseF.
588

One TCR heterodimer
TCRc~I3: CD3e = 1:2

B Two TCR heterodimers
TCRc~I3:CD3e = 1:2

C Two TCR heterodimers
TCRetI~: CD3e = 1:1
Figure 1.

Three models of TCK/CD3 stoichiometry.

ious solutions differ by the number of TCK c~ and B chains
present per complex and the ratio between the moles of TCK
fl (or TCR c~) and CD3 e represented in each complex. Models
proposing more than one TCR ot and TCK/~ in a single
complex predict that, on a cell expressing two different TCR
ot chains, antibodies specific for one T C R c~ would coprecipitate the other TCR a. Similarly, on cells expressing two
different TCK/3 chains, antibodies specific for one TCK/3
would coprecipitate the other TCR/3 chain. In the present
study, we have tested this prediction by generating cells that
coexpressed two different TCK ot and two different/3 chains
on their surfaces and have examined associations among complex components. The usefulness of such an approach, however, required that the two different TCR ot and two different
TCK/3 proteins be biochemically distinguishable.

The AND TCR oe and TCR ~ Chains Are Biochemically
Distinguishablefrom the H-Y TCR ce and TCR ~ Chains. We
compared the biochemical signatures of the T C R ot and/3
proteins expressed by mice transgenic for the AND TCK or~~3
(Y) with the biochemical signatures of the TCK c~ and
/3 chains expressed by mice transgenic for the receptor specific
for the male antigen H-Y (8) (hitherto referred to as the H-Y
TCR ot/fl receptor). Neither the AND and H-Y TCK ot
chains (^NDV~ll and H-W~3) nor the AND and H-Y TCR
/3 chains (^NDVa3 and a-YVa8 ) could be distinguished by
molecular weight or charge (data not shown). However, when
stripped of their carbohydrate side chains with Endo F/PNGase
F, which hydrolyze N-linked sugar residues, and then separated by charge, the two ot chains and the two/3 chains exhibited unique migration patterns when resolved by twodimensional NEPHGE under reducing conditions (Fig. 2).
The ^NDV~ll chain migrated as two spots, designated all1
and cd12 (Fig. 2) and the H-vV~3 chain migrated as a
significantly more acidic single spot, designated ~3. The

Stoichiometry of the TCK/CD3 Complex
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Cells. Thymi were dissected from young adult (6-8 wk) mice.
Single cell suspensions of thymocytes were prepared by gently teasing
cells from the thymic capsule and filtering over nylon mesh. Splenic
T ceilswere prepared by panning murine splenocyteson plates coated
with rabbit anti-mouse Ig (Organon Teknika, Durham, NC) to
rid the population of B cells and adherent ceils. Splenic CD4 +
(CDS-depleted) T cells were prepared from C57BL/6 mice by further treating the cells with anti-CD8 (3.155 [15]), anti-NKl.1
(PK136 [16]), anti-I-Ab'd,q (M5/114.15.2 [17]) and rabbit complement for 30 min at 370C, and then with rabbit complement alone
for another 30 rain at 37~ Viable cells were collected after centrifugation over Lympholyte-M (Cedarlane Laboratories, Ltd.,
Hornby, Canada).
Staining. Murine thymocytes and splenic T calls (5 x l0 s)
were stained with saturating concentrations of biotinylated and
FITC-conjugated reagents in 40 #1 for 30 min at 40C, washed in
200 #1 staining medium (HBSS, 0.1% BSA, 0.1% NAN3) three
times, then stained in 40 #1 with saturating concentrations of Texas
Red streptavidin for 15 min at 40C. Cells were washed again and
analyzed on a FACStar Plus| (Becton Dickinson & Co., Mountain
View, CA). For quantitative immunofluorescence of splenic T cells,
106 cells were washed and incubated at 40C for 1 h with unlabeled anti-TCK fl (H57-597), unlabeled anti-CD3e (145-2Cll or
500A2) at concentrations determined empirically to be saturating
(0.5 #g/ml for H57-597, 0.25 #g/ml for 145-2Cll, and 1.0 #g/ml
for 500A2). Because these antibodies share the same isotype (hamster IgG), their relative binding intensities could be compared
directly. After extensive washing, bound antibodies were visualized with FITC-conjugated goat anti-hamster antibody, which was
also used at saturating concentrations.
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ANDV/~3chain migrated as two major spots, designated/33t
and fl32, as did the "-YV~8 chain, designated/38t and/382.
The/382 spot generated by H-vVa8 was significantly lower
in molecular weight than any spot generated by ^NDVa3.
Most importantly, the two TCR o~ and the two TCR/3
chains were distinguishable from each other when anti-TCR
ol or anti-TCR/3 precipitations from AND and H-Y thymocytes were mixed together before NEPHGE analysis. In particular, the appearance of the c~3 and/382 spots, unique to
H-YV~3and H-vVo8, respectively, provided unambiguous evidence for the presence of the H-Y transgene products in immunoprecipitated preparations (Fig. 2).
AND/H-Y Double TCR TransgenicThymocytesand SplenoThymus

Spleen

Thymus

cytes CoexpressAND and H-Y TCR ~ and TCR ~ Proteins
on Their Surfaces. Because the AND and H-Y receptor proteins could be distinguished biochemically, we generated T
cells that coexpressed both receptors by crossing mice transgenic for the AND TCR odB receptor with mice transgenic
for the H-Y TCR ex/B. Immature and mature T lymphocytes in double TCR transgenic progeny expressed all four
transgenic TCR chains (*NDVall, H-W~3 [T3.70], ANDV~3,
and H-YVa8) on their surfaces simultaneously (Fig. 3). Surface staining revealed that the large majority of thymocytes
in double transgenic mice bound antibodies to both ^NDVa3
and H-YV/~8 as well as both ^NDVa11 and H-YVa3 (Fig. 3,
bottom left).
Spleen
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Figure 3. Thymocytes and splenocytes from
double TCR transgenic mice coexpress both TCR
o~and TCR/3 chains on their surfaces. Single cell
suspensions of thymocytes and splenic T cells from
single and double TCR transgenic littermates were
stained simultaneously with biotinyhted antibodies
specific for V~11 and fluorescein-conjugated antibodies specific for H-vV~3 (T3.70) or with biotinylated antibodies specific for ANDV~3 and
fluorescein conjugated antibodies specific for
H-vV08. Cells were washed, incubated with Texas
RM streptavidin, and analyzed on a FACStar Plus|
Quadrants define the boundaries of negative control profiles.
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Figure 2. Deglycosylated AND and H-Y TCR
cx chains and the AND and H-Y TCR. fl chains
are biochemicaUy distinguishable via two dimensional NEPHGE/SDS-PAGE anal)sis. Thymocytes
from AND transgenic and H-Y transgenic mice
were surface-labeled with lz5I, 1)sed in digitonin,
and precipitated with mAbs indicated. Precipitates
were digested' with Endo F, then resolved by
NEPHGE followed by SDS-PAGE under reducing
conditions, as indicated. Where indicated, precipitates from AND and H-Y 1)sates were mixed just
before electrophoresis. Separated proteins were
visualized by phosphorimagery.
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Immunoprecipitations supported the indication that AND
and H-Y TCR proteins were expressed on the surface of the
same cells. Antibodies to ANDV,,11 coprecipitated both
ANDVa3and H-YV~8, as shown by the appearance of the ~31,
~32, and the spot unique to H-Y, B82 (Fig. 4 A, left, see
arrow to the right). Reciprocally, ANDV~3coprecipitated both
ANDV~11 and H-YV~,3from double TCR transgenic thymocytes, as indicated by the presence of the ot111, c~112,and the
spot unique to H-Y, or3 (Fig. 4 A, middle, see arrow on the
left). Hence, TCR ot and TCR B chains of different transgenic origins shared the same receptor complex, indicating
(a) that they were expressed on the surface of the same cell
and (b) that the two transgenic TCP,, ot chains could freely
associate with each of the two transgenic TCR ~ chains.
Thymocytes and Splenic T Cells Express Only One TCR ce
and one TCR ~ per TCR/CD3 Complex. As expected, antiCD3e (2Cll) coprecipitated both ANDVa3 and ANDV~11
from single AND transgenic thymocytes and precipitated both
"-YV~8 and "-YV,,3 from single H-Y transgenic thymocytes.
Anti-CD3E also coprecipitated all transgenic TCR chains from
the surface of AND/H-Y double transgenic thymocytes as
indicated by the presence of ~81 and B82 spots and by the
presence of o~111, ol112, and c~3 spots (Fig. 4 A, right).
Although the AND TCR B and the H-Y TCR ~ chains
associated with both transgenic TCR c~ chains and with
CD3e, they never associated with each other. Antibodies to
ANDV,~11failed to coprecipitate H-YV~3 from the surface of
double transgenic thymocytes, for the spot unique to
H-YV,~3, i.e., c~3, was absent after NEPHGE analysis (Fig.
4 A, left, left arrow) Anti-H-vv~3 (T3.70) also failed to
precipitate spots unique to ANDV~ll (data not shown). Similarly, the two transgenic TCR/~ chains did not associate with
each other, for anti-ANnV~3 failed to precipitate the spot
unique to "-YV~8, i.e., ~82 (Fig. 4 A, middle, right arrow).
590

Thus, these data indicated that ANDVall and H-YVa3 were
both expressed on the surface of double transgenic thymocytes but were not present in the same complex. Likewise,
both ANDV~3 and H-YV~8 were present on the surface of
double TCR transgenic thymocytes, but were not present
in the same complex. Therefore, each TCR complex expressed
by double TCK transgenic thymocytes contained only one
TCK o~ and one TCR fl chain.
To address the possibility that stoichiometry of TCR complexes differed between immature and mature T cells, we examined the associations of transgenic TCR ex chains expressed
by splenic T cells from single (AND) and double (AND/
H-Y) transgenic mice (Fig. 4 B). Anti-V~11 precipitated
ANDv~11 from the surfaces of both AND single transgenic
and AND/H-Y double transgenic splenic T lysates, as shown
by the appearance of spots ot111 and ex112. However, antiV~11 did not coprecipitate H-YV~3, for the or3 spot was absent by NEPHGE analysis. As was observed in thymocytes,
these findings demonstrate that ANDVall was not present in
the same TCR complex that contained H-YV~3. We conclude that there is only one TCK cx per complex expressed
by mature T cells.
The TCR/CD3 Complex Contains One TCR or, One TCR
~, and Two CD3e Proteins. Our findings rule out models
of TCR/CD3 stoichiometry that propose more than one TCR
ot and one TCR ~ chain per complex (Fig. 1, B and C) and
also predict that CD3e chains outnumber TCR ~ chains on
the surface of T cells (Fig. 1 A). To quantify the relative expression levels of CD3e and TCR B proteins on normal T cells,
we compared the densities of TCR B and CD3e on normal
splenic T cells by immunofluorescence. When incubated with
saturating concentrations of anti-TCR. B (H57-597) or with
saturating concentrations of two different anti-CD3E antibodies (either 145-2Cll or 500A2), all of which share the

Stoichiometry of the TCR/CD3 Complex
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Figure 4. There is one TCR c~ and one TCR ~ chain per TCR/CD3
complex. Thymocytes from single and double TCR transgenic mice were
surface labeled with 12sI, precipitated with the indicated mAbs, and
digested with Endo F/PNGase as described under Materials and Methods.
Results are presented as described in Fig. 2. (A) ANDV~11 does not
coprecipitateH-YVa3and ANDVB3does not coprecipitate H-YVB8from the
surface of double TCR transgenic thymocytes. The arrows in the bottom
left corners indicate where the or3 spot migrates (right) or where it would
appear if H-YV,~3were present in the anti-ANDV~,11precipitate (left). The
arrows in the bottom right corners indicate either where the B82 spot
migrates (right) or where it would migrate if H-YVa8 were present in the
anti-ANDV~3 precipitate (center). Spots that are not labeled are minor species whose appearance is dependent on the extent of the exposure of the
gels. (B) ANDVc~lldoes not coprecipitate H-YV~3 from the surface of
double TCR transgenic splenic T cells. The arrow indicates where the
c~3 spot would appear if H-YV~,3were present in the anti-ANDV,~11precipitate. The spleen T cells were isolated from the same mice from which
the thymocytes were isolated for the studies shown in A.
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Spleen T

IOglo fluorescence

same isotype (hamster IgG) and subsequently incubated with
the same fluorescently tagged secondary antibody (goat
anti-hamster IgG), splenic T cells stained with anti-CD3e
fluoresced with greater intensity than those stained with antiTCR/3 (Fig. 5). When total fluorescence units were compared, precisely twice as much anti-CD3e bound the surface
of splenic T cells as anti-TCR/3, indicating that CD3e and
TCR/3 were present at a 2:1 ratio on the T cell surface.
Discussion

In the present study we assessed the stoichiometry of the
TCR ot and TCR fl chains in the TCR/CD3 complex expressed on the surface of immature and mature T cells. When
associations between different TCR ex and different TCR/3
chains of T lymphocytes from mice transgenic for two different
TCR cx//3 heterodimers were examined, it was dear that each
of the transgenic TCR c~ proteins freely associated with each
transgenic TCR/3 protein, and vice versa. However, no more
than one TCR ot and TCR/3 was ever detected in a single
TCR complex. Antibodies specific for one transgenic TCR
ot chain never coprecipitated the other transgenic TCR ot chain
and, reciprocally, antibodies against one transgenic TCR/3
chain never coprecipitated the other transgenic TCR/3 chain.
The absence of any association between either the transgenic
TCR oeprotein or the transgenic TCR/3 chains directly rules
out the existence of TCR complexes containing multiple independent TCR cx//3 pairs. The present data even rule out
models that postulate TCR complexes containing multiple
TCR ee//3 pairs where different individual TCR. ot or different
individual TCR/3 chains are constrained from sharing the
same complex. For example, even if the two transgenic TCR
r proteins ("-vV~3 and ^NDV,dl) were constrained from
sharing a single complex, each anti-Vt~ antibody would have
coprecipitated the other transgenic TCR 3 protein because
591
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Figure 5. There is a 1:2 ratio of binding sites for anti-TCR B and antiCD3e on the surface of T cells. Splenic CD4 + T cells were prepared and
stained for quantitative immunofluorescence as described under Materials
and Methods. Total fluorescent units (FU) x 10 -4 are displayed for each
curve in parantheses. FU = cell frequency x median intensity and median intensity is derived by converting median logarithmic channel numbers
to linear units via a calibration curve empirically derived for each logarithmic amplifier used. Negative control antibody fluorescence (lightly shaded)
is subtracted.

each transgenic TCR ot chain paired freely with both transgenic TCR/3 chains. Similarly, if the two transgenic TCR
/3 proteins ("-eVa8 and ^NDVa3) were incompatible, each
anti-V~ antibody would have coprecipitated the other transgenic TCR c~ protein because each transgenic TCR/3 chain
paired freely with both transgenic TCR r chains. The only
possibility that our data do not preclude is that TCR complexes on double transgenic mice exclusively contain multiple identical TCR or//3 pairs. Such a possibility would require V-region incompatibilities not only between the two
transgenic TCR cz proteins in different disulfide linked cx/3
dimers, but also between the two transgenic TCR/3 proteins. It is difficult to imagine a physical basis for such a severe constraint. Thus, we conclude that each TCR complex
contains only one TCR ot and one TCR/3 chain (Fig. 1 A).
Quantitative surface staining further demonstrates that
CD3e and TCR/3 are expressed on the surface of normal
T cells at a 2:1 ratio, as proposed in Fig. 1 A. Because the
anti-CD3e antibody 2Cll recognizes CD3e in association
with either CD3"y or CD3~, there are two e containing dimers
per TCP, complex (2~/e, 26e, or one of each), a stoichiometry previously advocated by the data and conclusions of de
la Hera et al. (4). However, the precise stoichiometry of CD3&
CD3% and ~"proteins still remains unknown. We cannot
reconcile our data with studies suggesting that CD3e and
TCR/3 are present on the surface of T cells in a 1:1 ratio
(21, 22), since our immunofluorescent assessment clearly indicates that TCR B and CD3e proteins are present in a 1:2
ratio. Therefore, the present study demonstrates that there
are precisely one TCR or, one TCR/3 and two CD3e proteins in a single TCK/CD3 complex.
What made it possible for us to assess associations between
the two different TCK c~ and the two different TCR/3 chains
in double transgenic mice were the distinctive patterns each
transgenic protein generated after they were stripped of their
N-linked oligosaccharides before NEPHGE analysis. Without
Endo F/PNGase digestion, the TCK proteins were indistinguishable, although u-YV,,3 was slightly more acidic than
^NDV,dl (data not shown). Every transgenic TCR protein
except "-vV~3 resolved into several spots after digestion.
These biochemical signatures were remarkably reproducible
and multiple additions of fresh Endo F/PNGase did not change
the pattern of spots generated. The multiple spots formed
by each TCR oe and TCR/3 chain during NEPHGE analysis
presumably represent the variety of TCR protein products
generated when mixed Endo F/PNGase activities act upon
a pool of heterogeneously glycosylated TCK cx and/3 chains.
It could also be a reflection of heterogeneity in accessibility
of individual chains to Endo F/PNGase digestion.
The possibility that there were more than one TCR cx//3
heterodimer per complex was originally raised to account for
a number of observations, the most compelling of which was
the recognition that an c~/fl/e ratio of 1:1:2 would result in
a transmembrane charge imbalance (5). Because TCR c~ and
TCK/3 chains have three positively charged transmembrane
residues between them and the CD3 proteins and ~"chains
each have one negatively charged transmembrane residue, a
TCR/CD3 complex with one TCR ~//3, two CD3es, one
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~"dimer, one CD3fi, and one CD37 would have a net charge
of -3. It is possible that as yet unidentified proteins and/or
lipids associate with the complex to maintain charge neutrality. A charge imbalance may, in fact, give the TCR/CD3
complex the flexibility to interact with different surface proteins at different times during activation or differentiation.
Alternatively, arithmetric calculations of net charge may not
take into account complexities introduced by tertiary structure which may mute the imbalance. It is also possible that
charge neutrality is not critical for stability of surface proteins. Indeed, the neu oncogene product is stably expressed
on the cell surface despite a net negative charge of - 1 within
its transmembrane domain (23).

Our findings offer an explanation also proposed by de la
Hera et al. (4) for data demonstrating a difference in the developmental and functional effects of anti-CD3e and antiTCR B (24-27). Because there are two CD3e chains per complex, anti-CD3e is capable of aggregating multiple receptor
complexes and generating intraceUular signals through multivalent cross-linking of TCR/CD3 components. However,
because there is only one TCR/~ chain per TCR complex
anti-TCR ~ can induce no more than bivalent TCR crosslinking. The signals transduced by bivalent rather than multivalent cross-linking may be quantitatively and qualitatively
distinct.

J. Punt is a recipient of the Damon Runyon-Waher Winchell postdoctoral fellowship, DP,G-064.
Address correspondence to Dr. J. Punt, Experimental Immunology Branch, National Cancer Institute,
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